| 33.06 -0.79 (-2.33%) | 06-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 42.39 |
1-year : | 45.38 |
| Resists | First : | 36.29 |
Second : | 38.86 |
| Pivot price | 35.71 |
|||
| Supports | First : | 32.15 |
Second : | 26.74 |
| MAs | MA(5) : | 34.55 |
MA(20) : | 35.95 |
| MA(100) : | 38.8 |
MA(250) : | 44.4 |
|
| MACD | MACD : | -0.8 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 6.6 |
D(3) : | 12.2 |
| RSI | RSI(14): 33.7 |
|||
| 52-week | High : | 59.9 | Low : | 32.15 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CNMD ] has closed below the lower bollinger band by 9.0%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ CNMD ] is to continue within current trading range. Bollinger Bands are 26.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 34.26 - 34.47 | 34.47 - 34.62 |
| Low: | 31.68 - 31.94 | 31.94 - 32.13 |
| Close: | 32.71 - 33.1 | 33.1 - 33.4 |
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
Wed, 03 Jun 2026
Director at CONMED (NYSE: CNMD) exercises 668 RSUs and receives 5,772-unit equity award - Stock Titan
Wed, 03 Jun 2026
CONMED (NYSE: CNMD) director gets 5,772 RSUs, converts 668 units - Stock Titan
Wed, 03 Jun 2026
CONMED (NYSE: CNMD) director awarded 5,772 RSUs and exercises 668 into shares - Stock Titan
Wed, 03 Jun 2026
Director Mark Kaye receives 5,772 RSUs at CONMED (NYSE: CNMD) - Stock Titan
Wed, 03 Jun 2026
CONMED (NYSE: CNMD) director awarded 5,772 RSUs and converts 668 into common stock - Stock Titan
Tue, 02 Jun 2026
Q1 Earnings Outperformers: CONMED (NYSE:CNMD) And The Rest Of The Surgical Equipment & Consumables - Diversified Stocks - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 30 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 116.3 (%) |
| Shares Short | 2,290 (K) |
| Shares Short P.Month | 2,310 (K) |
| EPS | 1.76 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 33.75 |
| Profit Margin | 4 % |
| Operating Margin | 10 % |
| Return on Assets (ttm) | 3.7 % |
| Return on Equity (ttm) | 5.5 % |
| Qtrly Rev. Growth | -1.3 % |
| Gross Profit (p.s.) | 24.6 |
| Sales Per Share | 45.49 |
| EBITDA (p.s.) | 6.99 |
| Qtrly Earnings Growth | 136.8 % |
| Operating Cash Flow | 143 (M) |
| Levered Free Cash Flow | 126 (M) |
| PE Ratio | 18.67 |
| PEG Ratio | 1.8 |
| Price to Book value | 0.97 |
| Price to Sales | 0.72 |
| Price to Cash Flow | 6.97 |
| Dividend | 0.2 |
| Forward Dividend | 0 |
| Dividend Yield | 0.6% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|